EAM Investors’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

EAM Investors’s Portfolio ICPT Stock Details ICPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-12,706	Closed	-$1.57M	–	308
2019 Q4	$1.57M	Buy	+12,706	New	+$1.14M	0.35%	130
2014 Q2	–	Sell	-5,124	Closed	-$1.69M	–	379
2014 Q1	$1.69M	Sell	5,124 -29,632	-85%	-$10M	0.3%	122
2013 Q4	$2.37M	Buy	34,756 +1,536	+5%	+$88.8K	0.42%	61
2013 Q3	$2.29M	Buy	+33,220	New	+$1.64M	0.46%	53

Other funds holding ICPT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SCM

Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return

Senvest Management New York $3.01B AUM 35.7% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

EAM Investors's ICPT Position: Q1 2020 in Review

EAM Investors sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q1 2020, closing a stake of 12,706 shares — an estimated $1.57M sold.

EAM Investors first reported a position in ICPT in Q3 2013 and held it in 4 quarters. The position peaked at $2.37M in Q4 2013. 188 funds tracked by Wall St. Rank hold ICPT as of Q1 2020.

EAM Investors reported no remaining Intercept Pharmaceuticals, Inc. position as of Q1 2020 after selling out during the quarter.
EAM Investors sold 12,706 Intercept Pharmaceuticals, Inc. shares in Q1 2020, an estimated $1.57M.
EAM Investors first reported a position in Intercept Pharmaceuticals, Inc. in Q3 2013 and held it in 4 quarters.
EAM Investors's Intercept Pharmaceuticals, Inc. position peaked at $2.37M in Q4 2013.
188 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q1 2020.

Based on EAM Investors's 13F filing for Q1 2020, filed 13 May 2020.